Sotera Health Company
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-68.5% vs price
Base Case (Median)
-57.8% vs price
Bull Case (75th pct.)
-24.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $6.61 | -64.9% | High (40%) |
| PE Comparable | $12.68 | -32.5% | Medium (25%) |
| Growth Trajectory DCF | $47.99 | 155.3% | Medium (20%) |
| Graham Number | $5.23 | -72.2% | Medium (40%) |
| EV/EBITDA | $15.57 | -17.2% | Medium (20%) |
| EV/FCF | $7.94 | -57.8% | Medium (20%) |
| Earnings Power Value | $2.54 | -86.5% | Medium (50%) |
Based on 7 out of 8 methods, SHC appears overvalued at the current price of $18.80. The base case fair value of $7.94 implies 57.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.